Lysophosphatidyicholine (lysoPC), a component of atherogenic lipoproteins and atherosclerotic lesions, has been recently suggested to play a role in atherogenesis. LysoPC is known to induce several endothelial genes involved in leukocyte recruitment, mitogenesis, and inflammation. Cyclooxygenases (prostaglandin H2 synthases) are rate-limiting enzymes involved in the endothelial synthesis of prostacyclin, an antiplatelet, vasorelaxant, and vasoprotective molecule. We investigated the effect of lysoPC on the endothelial expression of cyclooxygenases. Our results demonstrate that, in cultured human umbilical vein endothelial cells, lysoPC induces cyclooxygenase-2 mRNA and protein levels. Increased expression of cyclooxygenase-2 is accompanied by the enhancement of both basal-and calcium ionophore A23187-induced synthesis of prostacyclin. Nuclear runoff experiments demonstrated an increased rate of transcription of the cyclooxygenase-2 gene by lysoPC. In contrast, lysoPC did not affect the expression of constitutive cyclooxygenase-1. Our results suggest that the induction of endothelial cyclooxygenase-2 by lysoPC may be an important vasoprotective mechanism that limits progression of atherosclerotic lesions and promotes their regression. (J.
Introduction
Cyclooxygenases (COX,' prostaglandin H2 synthases) are key rate-limiting enzymes in the synthesis of prostanoids from arachidonic acid (1) . Two isoforms of COX have been described glyceraldehyde-3-phosphate dehydrogenase; HUVEC, human umbilical vein endothelial cells; lysoPC, lysophosphatidylcholine. so far (2) (3) (4) (5) (6) . COX-1 is constitutively expressed in many cell types. In contrast, expression of COX-2 requires stimulation of cells with cell-specific extracellular signals such as autacoids, hormones, growth factors, and cytokines (7, 8) . Both isoforms of COX have been reported to be expressed in human umbilical vein endothelial cells (HUVEC) (9) (10) (11) (12) .
The major prostanoid synthesized by vascular endothelium is prostacyclin (PGI2) (13) which regulates various physiological processes occurring at the interphase between the blood and vascular wall. Biological actions of prostacylin include inhibition of platelet aggregation and adhesion, inhibition of vascular smooth muscle tone and growth, inhibition of leukocyte activation and adhesion, and reduction of cholesteryl ester accumulation in cells of the vessel wall (14) . These biological actions of prostacyclin and its efficacy in the treatment of complications of atherosclerosis such as peripheral vascular disease (15, 16) suggest that prostacylin is an endogenous antiatherogenic molecule.
Several lines of evidence suggest a role for lysophosphatidylcholine (lysoPC) in atherogenesis (17) . The lysoPC content of atherosclerotic arteries is severalfold higher than that of normal vessels (18). After proatherogenic modifications of LDLs, lysoPC may constitute up to 40% of their total lipid content (19) . LysoPC is an essential component of oxidized proatherogenic lipoproteins responsible for their chemotactic effect on human monocytes (20, 21) and mitogenic effect on murine macrophages (22) . LysoPC induces monocytic cell expression of heparin-binding epidermal growth factor (23) . Importantly, lysoPC causes induction of several endothelial genes expressed in early atherosclerosis, such as vascular adhesion molecule-i, intercellular adhesion molecule-i, PDGF chains A and B, and heparinbinding EGF (24, 25) . agarose and transferred to a positively charged nylon membrane. As COX-1 probe we used agarose gel-purified full-length COX-1 cDNA cloned in our laboratory (11) . As COX-2 probe we used agarose gelpurified full-length 1.94-kb COX-2 cDNA which was obtained from Dr. Timothy Hla (9) . Probe labeling, hybridization, and chemiluminescent detection were performed using components of Genius system (Boeh- 12, and 24 h using digoxigenin-labeled COX-l cDNA probe. (B) Autoe-GAPDH radiogram of the same membrane as in A after stripping and rehybridization using digoxigenin-labeled COX-2 probe. (C) Autoradiogram of the same membrane as in A and B after stripping and rehybridization using digoxigenin-labeled GAPDH probe. These experiments were repeated twice with similar results. of 2.8-kb COX-l mRNA in cultured HUVEC, as determined by Northern blotting (Fig. 1 A) . Densitometric analysis revealed that lysoPC-induced increases of COX-1 mRNA levels were < 1.5-fold. In contrast, lysoPC (100 MM) caused a marked timedependent induction of -4-4.5-kb COX-2 mRNA (Fig. 1 B) . COX-2 mRNA levels reached a maximum 3 h after the stimulation with lysoPC. Interestingly, in addition to 4-4.5-kb COX-2 mRNA, our COX-2 probe hybridized to a distinct 2.8-kb mRNA (Fig. 1 B) . Despite a similar size as that of COX-1 mRNA, this 2.8-kb band is unlikely to be a result of crosshybridization of our COX-2 probe to COX-1 mRNA because this mRNA species is not present in unstimulated HUVEC. Moreover, this 2.8-kb mRNA was clearly inducible by lysoPC with a time-course identical to that of induction of COX-2. This suggests that this 2.8-kb mRNA species is related to COX-2.
Western blotting analysis revealed that the induction of COX-2 mRNA by lysoPC was paralleled by the appearance of COX-2 protein (Fig. 2 ). COX-2 protein level reached a peak 3 h after stimulation with lysoPC (100 MM) and remained detectable for at least 24 h after stimulation of HUVEC with lysoPC. The lowest concentration of lysoPC that was able to induce COX-2 protein expression after 3 h of stimulation with lysoPC was 50 MM. LysoPC at 30 MM was without effect (n = 2, not shown). As shown in Fig. 2 , the antibody used for detection of COX-2 did not cross-react with COX-1. Western blotting analysis of HUVEC lysates using anti-COX-1 antibody revealed the presence of a 72/74-kD doublet. The higher molecular weight band was clearly inducible by lysoPC with a time-course similar to that of induction of COX-2. The lower molecular weight band did not change after stimulation with lysoPC. These results raised suspicions as to the isoform specificity of our COX-1 antibody. Indeed, as shown in Fig. 2 , the COX-1 antibody crossreacted with COX-2. Therefore, it is likely that the higher molecular weight band of the doublet in Fig. 2 A may represent mainly lysoPC-inducible COX-2 and the lower molecular weight band of the doublet may represent mainly noninducible COX-1.
To establish whether induction of COX-2 by lysoPC is due to the activation of the COX-2 gene we performed nuclear runoff experiments. As seen in Fig. 3 (Fig. 3 ) and f-tubulin or GAPDH genes (data not shown).
To establish whether induction of COX-2 in HUVEC has the expected functional consequence for the endothelial synthesis of prostacyclin, we determined the production of 6-keto-PGFiar, a stable product of hydrolysis of prostacyclin, by control and lysoPC-stimulated HUVEC. As shown on Fig. 4 , incubation of HUVEC for 12 h with lysoPC (100 sM) approximately doubled basal prostacyclin synthesis whereas prostacyclin release in response to calcium ionophore A23187 was increased about fivefold.
Discussion
The major finding of this communication is demonstration of the induction of COX-2 in cultured human umbilical vein endo- Induction of COX-2 by lysoPC may have profound consequences for the endothelial function, as it resulted in the enhanced synthesis of prostacyclin. Our experiments demonstrated that both the basal as well as calcium ionophore A23187-stimulated synthesis of prostacyclin were increased in HUVEC stimulated with lysoPC. These results, when considered in conjunction with the evidence for the simultaneous induction of COX-2 expression, implicate that COX-2 plays a pivotal role in lysoPCinduced enhancement of prostacyclin synthesis.
Although it is well recognized that COX-2 can be induced in many cell-types, including HUVEC, by cytokines and mitogenic factors, to our knowledge, induction of COX-2 by a lipid mediator such as lysoPC is a novel observation. This finding raises several intriguing questions regarding the biological significance of lysoPC-triggered induction of COX-2 expression, the 
Our findings of the induction of COX-2 but not of COX-1 in HUVEC by lysoPC are in keeping with current concepts regarding the roles of cyclooxygenase isoforms in controlling prostanoid synthesis (7) . COX-1 is expressed constitutively in many cell types, including endothelial cells, whereas expression of COX-2 requires stimulation of cells with cytokines, mitogens, or other cell-specific signals. The COX-1 gene is regulated by a tight control mechanism whereas the COX-2 gene is highly inducible. As we have recently demonstrated (29) , COX-1 is rapidly degraded during catalysis and, therefore, has only a limited capacity to support elevated synthesis of prostanoids in stimulated endothelial cells. These properties of COX-1 suggest that it plays a major role in the basal synthesis of prostanoids. In contrast, rapid induction of COX-2 is required for augmenting prostanoids synthesis in response to extracellular stimuli.
As outlined in the introduction, lysoPC is believed to play a role in the pathogenesis of atherosclerosis. Several biological actions of lysoPC are consistent with the function of lysoPC as a proatherogenic molecule (17) (18) (19) (20) (21) (22) (23) (24) (25) . Surprisingly, we have recently shown that lysoPC enhances the endothelial expression of nitric oxide synthase type HI (25a) which is believed to be an important antiatherogenic and vasoprotective enzyme. As prostacycin, the major endothelium-derived prostanoid, is a vasoprotective, antithrombotic, antiplatelet, growth-suppressant molecule (14) , the induction of COX-2 may be considered as another example of induction by lysoPC of a vasoprotective and potentially antiatherogenic endothelial gene. However, several reservations have to be made at this point because the role of cyclooxygenases and prostanoids in the pathogenesis of atherogenesis are currently poorly understood (30) . Our results are consistent with observations demonstrating that oxidized LDL enhance the endothelial synthesis of prostacyclin (31, 32) as well as COX-2 mRNA levels (33) . However, the effects of atherosclerosis on prostanoid synthesis in humans or experimental animals have not been conclusively established as increased (34, 35) , biphasic (28) and reduced prostanoid (36) synthesis have been reported. Similarly, contradictory effects of nonselective inhibitors of COX on the development of experimental atherosclerosis have been observed (37-39), and the effects of isoform-selective COX inhibitors have not been described yet. We are also unaware of studies investigating cellular distribution of COX-isoforms in human atherosclerotic lesions or animal models of atherosclerosis. Importantly, it is also not known whether lysoPC induces COX-2 in other cellular components of atherosclerotic lesions such as macrophages or vascular smooth muscle cells. In contrast to endothelium, induction of COX-2 in these cells may lead to the production of mainly proinflammatory prostanoids which may contribute to the vascular damage. These limitations preclude any definitive statement about the overall role of induction of COX-2 by lysoPC in the atherogenesis. However, the biological actions of prostacyclin, a major endothelium-derived prostanoid, support the notion that the endothelial expression of COX-2 is a vasoprotective mechanism. It can be conceived that the induction of COX-2 by lysoPC is a back-up mechanism necessary to support elevated synthesis of vasoprotective prostacyclin by stressed endothelial cells. In this context, it is important to note that the vasoprotective and antiatherogenic actions of prostacyclin and nitric oxide significantly overlap and sometimes, as in the case of inhibition of platelet aggregation (40) 
